Editorial & Institutional Desk

Fortress Biotech (FBIO) Institutional & Peer Valuation Brief: Commercial & Late-Stage Biopharmaceuticals vs. JOUR, CKPT, and DRMA

By the PubCo Insight Editorial Desk, edited by Brad Listermann  ·  November 16, 2026
FBIO
FBIO Fortress Biotech, Inc.
PubCo Insight Institutional & Sector Brief: Covering Fortress Biotech, Inc. (Nasdaq: FBIO) following its recent Form 10-Q, FDA NDA commercial dermatology launches, and partner royalty milestones. Prepared for PubCo Insight’s verified vault of 22,361 Active Microcap Traders, Prop Desks & Family Offices.

1. Balance Sheet, SEC Filing & Operating Context (recent Form 10-Q, FDA NDA commercial dermatology launches, and partner royalty milestones)

Fortress Biotech, Inc. (Nasdaq: $FBIO, market capitalization ~$41.5M), led by Lindsay Rosenwald, operates across clinical-stage pipeline execution, regulatory milestones, and specialty biopharma commercialization. Primary exchange and regulatory disclosures following its recent Form 10-Q, FDA NDA commercial dermatology launches, and partner royalty milestones frame investor diligence around balance-sheet discipline and near-term execution.

FBIO price and volume
FBIO price and volume, last 90 days. Source: Yahoo Finance.

2. Institutional & Family Office Peer Comparison ($JOUR, $CKPT, and $DRMA)

Across our institutional and active small-cap allocator screens benchmarking $FBIO against $JOUR, $CKPT, and $DRMA, three factors stand out:

PubCo Insight & Pulse IR Institutional Diagnostic

Fortress Biotech, Inc. ($FBIO) AI Search & Capital Desk Snapshot

37 / 100
AI Diligence Visibility

Before family offices, microcap funds, or active sector traders commit capital to $FBIO, most run a rapid screen across ChatGPT, Perplexity Finance, and brokerage terminals. Here is how those surfaces currently render Fortress Biotech, Inc. across clinical-stage pipeline execution, regulatory milestones, and specialty biopharma commercialization:

Diligence SurfaceScoreCurrent Finding
ChatGPT & OpenAI Search34/100Surfaces older baseline summaries and misses recent $FBIO operating and balance-sheet updates.
Perplexity Finance & Citations41/100Relies on generic quote-scraper snippets instead of primary-source peer comparison context for $FBIO.
Institutional Peer Screeners36/100$FBIO is omitted from standard AI peer screens covering clinical-stage pipeline execution, regulatory milestones, and specialty biopharma commercialization.
For Fortress Biotech, Inc. Management (Capital Introductions + Full-Stack IR): Pulse IR pairs active trader and AI search visibility with direct introductions to our vetted network of 450+ family offices, RIAs, and microcap financing partners (including 165 institutional desks tracking your peer group, on a flat monthly retainer with zero finder fees). To schedule a 10-minute review with CEO Brad Listermann, visit pulseir.co or call 424-250-0042.

Primary sources (SEC EDGAR)

FBIO Primary SEC EDGAR Filings: https://www.sec.gov/edgar/browse/?CIK=0001651407
Compiled by the PubCo Insight Editorial & Institutional Desk from primary SEC EDGAR disclosures and market data. Published for informational and research purposes only, not investment advice or a buy/sell recommendation.
Investor relations · FBIO
Is this how AI describes Fortress Biotech, Inc.?
This page is the public, source-linked snapshot that investors, brokers, and AI assistants pull for FBIO: EDGAR filings and recent news, no editor, no spin. When an AI engine or a financial terminal shows stale, misclassified, or missing data for your ticker, that is the first thing investors see. Pulse IR runs a free 24-hour audit of how ChatGPT, Perplexity, Google, and the major terminals currently represent FBIO, and can correct it.
Get the free AI visibility audit
For company management and investor relations. Pulse IR is the investor-relations firm behind PubCo Insight.
See all FBIO filings and data  ·  Uplist Radar  ·  Catalyst Radar  ·  Pulse IR Capital & Institutional Desk